Prima's ovarian cancer drug wins fast-track status from FDA

05/9/2014 | Australian Life Scientist

The FDA has granted fast-track designation to Prima BioMed's experimental drug CVac as a treatment for relapsed platinum-sensitive epithelial ovarian cancer. The drug also holds orphan drug status in both the U.S. and Europe. The designation is an "important milestone" for Prima and a "recognition of the serious nature of ovarian cancer and the clear unmet medical need to develop new treatments for relapsed platinum-sensitive ovarian cancer in remission," CEO Matthew Lehman said.

View Full Article in:

Australian Life Scientist

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC